- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
AOS1 Antibody (N-term) Blocking PeptideSynthetic peptide
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| BP2511a | 0.1 mg 400 ul | In Stock | $ 45.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
AOS1 Antibody (N-term) Blocking Peptide - Product info | |
| Primary Accession | Q9UBE0 |
| Clone Names | 2120209 |
| Calculated MW | 38450 Da |
AOS1 Antibody (N-term) Blocking Peptide - Additional info | |
| Gene ID 10055 | |
| Target/Specificity The synthetic peptide sequence used to generate the antibody AP2511a was selected from the N-terminal region of human AOS1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. | |
| Format The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. | |
| Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. | |
AOS1 Antibody (N-term) Blocking Peptide - Protein Information | |
| Name SAE1 | |
| Synonyms AOS1, SUA1, UBLE1A | |
| Function The heterodimer acts as a E1 ligase for SUMO1, SUMO2, SUMO3, and probably SUMO4. It mediates ATP-dependent activation of SUMO proteins followed by formation of a thioester bond between a SUMO protein and a conserved active site cysteine residue on UBA2/SAE2 | |
| Cellular Location Nucleus. | |
| Tissue Location Expression level increases during S phase and drops in G2 phase (at protein level) | |
AOS1 Antibody (N-term) Blocking Peptide - Related products
AP1199a: SAE1 (AOS1) Antibody (N-term)
AP1199b: SAE1 (AOS1) Antibody (C-term)
AP2011b: SAE1 (AOS1) Antibody (C-term)
AP2511a: SAE1 (AOS1) Antibody (N-term)
AP2511b: SAE1 (AOS1) Antibody (C-term)
LY10831a: SAE1 Over-expression Lysate
BP1199a: SAE1 Antibody (N-term) Blocking Peptide
BP1199b: SAE1 Antibody (C-term) Blocking Peptide
BP2011b: SAE1 Antibody (C-term) Blocking Peptide
BP2511a: AOS1 Antibody (N-term) Blocking Peptide
BP2511b: AOS1 Antibody (C-term) Blocking Peptide
AOS1 Antibody (N-term) Blocking Peptide - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
The dimeric enzyme AOS1 acts as a an E1 ligase for SUMO1, SUMO2, SUMO3, and probably SUMO4. It mediates ATP-dependent activation of SUMO proteins and formation of a thioester with a conserved cysteine residue on SAE2.
REFERENCES
Desterro, J.M., et al., J. Biol. Chem. 274(15):10618-10624 (1999).Gong, L., et al., FEBS Lett. 448(1):185-189 (1999).Okuma, T., et al., Biochem. Biophys. Res. Commun. 254(3):693-698 (1999).
